Description of the medicine: Ranitidine (Ranitidine)
N- [2 - [[[5- (Dimethylamino) methyl] furfuryl] thio] ethyl] -N'-methyl-2-nitro-1, 1-ethylenediamine.
Synonyms: Acyloc, Peptoran, Ranigast, Ranisan, Ulcuran, Acidex, Acilok E, Anistal, Danitin, Istomar, Peptoran, Ranacid, Ranigast, Ranidil, Raniplex, Ranisan, Ranisen, Ranx, Taural, Ulcoren, Ulcuran, Ulsal, Vizerul, Zantac and etc.
Ranitidine is an antagonist of H 2 -receptors. By action is close to cimetidine. By binding to H 2 -receptors of parietal cells of the gastric mucosa, it suppresses basal and stimulated gastric secretion, the secretion of hydrochloric acid and pepsin.
The drug is rapidly absorbed when taken orally. The peak concentration in the blood plasma after a single dose is observed after 1 to 3 hours. The duration of inhibition of secretion is 8 to 12 hours. It is excreted by the kidneys, mostly unchanged, in part as metabolites.
Indications for use are the same as for cimetidine. According to available data, ranitidine is more effective and better tolerated than cimetidine. Effective in smaller doses than cimetidine.
Assign adults usually 150 mg (1 tablet) 2 times a day (morning and evening), regardless of the time of food intake; With Zollinger-Ellison syndrome - 1 tablet 3 times a day. The duration of the course of treatment ranitidine 4-8 weeks.
Sufficient experience of use in children has not accumulated until recently, therefore it is not recommended to prescribe it to children under the age of 14 years.
Ranitidine is relatively well tolerated, side effects are less common than with cimetidine, but headache, dizziness, constipation or diarrhea, nausea, in rare cases, skin rash, liver dysfunction.
When violations of kidney function take the drug in smaller doses - 150 mg at night.
The drug should not be prescribed during pregnancy and lactation.
Unlike cimetidine, ranitidine does not significantly affect the detoxification function of the liver and does not potentiate the effects of coumarins, diphenine, diazepam (sibazone), and other drugs.
Form release: a tablet of 0.15 g (150 mg).